Syntara Ltd - Asset Resilience Ratio

Latest as of June 2005: 85.55%

Syntara Ltd (SNT) has an Asset Resilience Ratio of 85.55% as of June 2005. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check SNT strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

AU$32.45 Million
≈ $22.96 Million USD Cash + Short-term Investments

Total Assets

AU$37.94 Million
≈ $26.84 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2005–2023)

This chart shows how Syntara Ltd's Asset Resilience Ratio has changed over time. See SNT net asset quality score to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Syntara Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Syntara Ltd market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$0.00 0%
Short-term Investments AU$32.45 Million 85.55%
Total Liquid Assets AU$32.45 Million 85.55%

Asset Resilience Insights

  • Very High Liquidity: Syntara Ltd maintains exceptional liquid asset reserves at 85.55% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Syntara Ltd Industry Peers by Asset Resilience Ratio

Compare Syntara Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Tasly Pharmaceutical Group Co Ltd
SHG:600535
Drug Manufacturers - Specialty & Generic 11.69%
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
Drug Manufacturers - Specialty & Generic 6.62%
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131
Drug Manufacturers - Specialty & Generic 1.37%
Bausch Health Companies Inc
TO:BHC
Drug Manufacturers - Specialty & Generic 4.97%
Dezhan HealthCare Co Ltd
SHE:000813
Drug Manufacturers - Specialty & Generic 0.15%
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390
Drug Manufacturers - Specialty & Generic 0.01%
Hainan Haiyao Co Ltd
SHE:000566
Drug Manufacturers - Specialty & Generic 3.27%
Shanxi Zhendong Pharmaceutical
SHE:300158
Drug Manufacturers - Specialty & Generic 10.74%

Annual Asset Resilience Ratio for Syntara Ltd (2005–2023)

The table below shows the annual Asset Resilience Ratio data for Syntara Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2023-06-30 36.40% AU$8.75 Million
≈ $6.19 Million
AU$24.03 Million
≈ $17.00 Million
+2.67pp
2022-06-30 33.73% AU$8.49 Million
≈ $6.01 Million
AU$25.19 Million
≈ $17.82 Million
-51.82pp
2005-06-30 85.55% AU$32.45 Million
≈ $22.96 Million
AU$37.94 Million
≈ $26.84 Million
--
pp = percentage points

About Syntara Ltd

AU:SNT Australia Drug Manufacturers - Specialty & Generic
Market Cap
$28.89 Million
AU$40.83 Million AUD
Market Cap Rank
#23929 Global
#943 in Australia
Share Price
AU$0.03
Change (1 day)
+4.17%
52-Week Range
AU$0.02 - AU$0.06
All Time High
AU$0.40
About

Syntara Limited operates as a clinical-stage drug development company that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia. Its lead product candidate, amsulostat, is being developed for the treatment of bone marrow cancer myelofibrosis and i… Read more